Defining success in clinical trials of diabetic foot wounds: The Los Angeles DFCon consensus

David G. Armstrong, Andrew J M Boulton, George Andros, Christopher Attinger, David Eisenbud, Lawrence A. Lavery, Benjamin A. Lipsky, Joseph L. Mills, Gary Sibbald, Adrianne P. Smith, Dane Wukich, David J. Margolis

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Regulatory requirements for new products should be guided by clinical trials that protect the public by a thorough evaluation of safety and efficacy, while not creating unnecessary barriers to their development and ultimate approval. While healing a wound is the ultimate goal of treating an individual with a diabetic foot ulcer, achieving this goal is physiologically complex requiring the initiation and interaction of many events and therefore unlikely to be achieved by one compound. We believe that developing new, more meaningful, study outcomes or end points in wound care trials would both aid in determining the true efficacy of wound management modalities and facilitate the product development cycle. The primary guidance from the US Food and Drug Administration to industry in this field was published in 2006. This document, while helpful and largely in concert with current knowledge of wound healing, needs to be substantially improved. We therefore convened an interdisciplinary task force comprising experts in various aspects of wound care to attempt to achieve consensus in defining primary outcomes and potential secondary endpoints for various classes of wound-healing modalities.

Original languageEnglish (US)
Pages (from-to)211-213
Number of pages3
JournalInternational Wound Journal
Volume6
Issue number3
DOIs
StatePublished - Jun 2009

Fingerprint

Diabetic Foot
Los Angeles
Wound Healing
Clinical Trials
Wounds and Injuries
Advisory Committees
United States Food and Drug Administration
Industry
Outcome Assessment (Health Care)
Safety

Keywords

  • Amputation
  • Consensus
  • Diabetes
  • FDA
  • Healing
  • Infection
  • Outcomes
  • Ulcer

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Armstrong, D. G., Boulton, A. J. M., Andros, G., Attinger, C., Eisenbud, D., Lavery, L. A., ... Margolis, D. J. (2009). Defining success in clinical trials of diabetic foot wounds: The Los Angeles DFCon consensus. International Wound Journal, 6(3), 211-213. https://doi.org/10.1111/j.1742-481X.2009.00598.x

Defining success in clinical trials of diabetic foot wounds : The Los Angeles DFCon consensus. / Armstrong, David G.; Boulton, Andrew J M; Andros, George; Attinger, Christopher; Eisenbud, David; Lavery, Lawrence A.; Lipsky, Benjamin A.; Mills, Joseph L.; Sibbald, Gary; Smith, Adrianne P.; Wukich, Dane; Margolis, David J.

In: International Wound Journal, Vol. 6, No. 3, 06.2009, p. 211-213.

Research output: Contribution to journalArticle

Armstrong, DG, Boulton, AJM, Andros, G, Attinger, C, Eisenbud, D, Lavery, LA, Lipsky, BA, Mills, JL, Sibbald, G, Smith, AP, Wukich, D & Margolis, DJ 2009, 'Defining success in clinical trials of diabetic foot wounds: The Los Angeles DFCon consensus', International Wound Journal, vol. 6, no. 3, pp. 211-213. https://doi.org/10.1111/j.1742-481X.2009.00598.x
Armstrong, David G. ; Boulton, Andrew J M ; Andros, George ; Attinger, Christopher ; Eisenbud, David ; Lavery, Lawrence A. ; Lipsky, Benjamin A. ; Mills, Joseph L. ; Sibbald, Gary ; Smith, Adrianne P. ; Wukich, Dane ; Margolis, David J. / Defining success in clinical trials of diabetic foot wounds : The Los Angeles DFCon consensus. In: International Wound Journal. 2009 ; Vol. 6, No. 3. pp. 211-213.
@article{52e19f4db934449584d59848b64fd7a5,
title = "Defining success in clinical trials of diabetic foot wounds: The Los Angeles DFCon consensus",
abstract = "Regulatory requirements for new products should be guided by clinical trials that protect the public by a thorough evaluation of safety and efficacy, while not creating unnecessary barriers to their development and ultimate approval. While healing a wound is the ultimate goal of treating an individual with a diabetic foot ulcer, achieving this goal is physiologically complex requiring the initiation and interaction of many events and therefore unlikely to be achieved by one compound. We believe that developing new, more meaningful, study outcomes or end points in wound care trials would both aid in determining the true efficacy of wound management modalities and facilitate the product development cycle. The primary guidance from the US Food and Drug Administration to industry in this field was published in 2006. This document, while helpful and largely in concert with current knowledge of wound healing, needs to be substantially improved. We therefore convened an interdisciplinary task force comprising experts in various aspects of wound care to attempt to achieve consensus in defining primary outcomes and potential secondary endpoints for various classes of wound-healing modalities.",
keywords = "Amputation, Consensus, Diabetes, FDA, Healing, Infection, Outcomes, Ulcer",
author = "Armstrong, {David G.} and Boulton, {Andrew J M} and George Andros and Christopher Attinger and David Eisenbud and Lavery, {Lawrence A.} and Lipsky, {Benjamin A.} and Mills, {Joseph L.} and Gary Sibbald and Smith, {Adrianne P.} and Dane Wukich and Margolis, {David J.}",
year = "2009",
month = "6",
doi = "10.1111/j.1742-481X.2009.00598.x",
language = "English (US)",
volume = "6",
pages = "211--213",
journal = "International Wound Journal",
issn = "1742-4801",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Defining success in clinical trials of diabetic foot wounds

T2 - The Los Angeles DFCon consensus

AU - Armstrong, David G.

AU - Boulton, Andrew J M

AU - Andros, George

AU - Attinger, Christopher

AU - Eisenbud, David

AU - Lavery, Lawrence A.

AU - Lipsky, Benjamin A.

AU - Mills, Joseph L.

AU - Sibbald, Gary

AU - Smith, Adrianne P.

AU - Wukich, Dane

AU - Margolis, David J.

PY - 2009/6

Y1 - 2009/6

N2 - Regulatory requirements for new products should be guided by clinical trials that protect the public by a thorough evaluation of safety and efficacy, while not creating unnecessary barriers to their development and ultimate approval. While healing a wound is the ultimate goal of treating an individual with a diabetic foot ulcer, achieving this goal is physiologically complex requiring the initiation and interaction of many events and therefore unlikely to be achieved by one compound. We believe that developing new, more meaningful, study outcomes or end points in wound care trials would both aid in determining the true efficacy of wound management modalities and facilitate the product development cycle. The primary guidance from the US Food and Drug Administration to industry in this field was published in 2006. This document, while helpful and largely in concert with current knowledge of wound healing, needs to be substantially improved. We therefore convened an interdisciplinary task force comprising experts in various aspects of wound care to attempt to achieve consensus in defining primary outcomes and potential secondary endpoints for various classes of wound-healing modalities.

AB - Regulatory requirements for new products should be guided by clinical trials that protect the public by a thorough evaluation of safety and efficacy, while not creating unnecessary barriers to their development and ultimate approval. While healing a wound is the ultimate goal of treating an individual with a diabetic foot ulcer, achieving this goal is physiologically complex requiring the initiation and interaction of many events and therefore unlikely to be achieved by one compound. We believe that developing new, more meaningful, study outcomes or end points in wound care trials would both aid in determining the true efficacy of wound management modalities and facilitate the product development cycle. The primary guidance from the US Food and Drug Administration to industry in this field was published in 2006. This document, while helpful and largely in concert with current knowledge of wound healing, needs to be substantially improved. We therefore convened an interdisciplinary task force comprising experts in various aspects of wound care to attempt to achieve consensus in defining primary outcomes and potential secondary endpoints for various classes of wound-healing modalities.

KW - Amputation

KW - Consensus

KW - Diabetes

KW - FDA

KW - Healing

KW - Infection

KW - Outcomes

KW - Ulcer

UR - http://www.scopus.com/inward/record.url?scp=67650754178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650754178&partnerID=8YFLogxK

U2 - 10.1111/j.1742-481X.2009.00598.x

DO - 10.1111/j.1742-481X.2009.00598.x

M3 - Article

C2 - 19538193

AN - SCOPUS:67650754178

VL - 6

SP - 211

EP - 213

JO - International Wound Journal

JF - International Wound Journal

SN - 1742-4801

IS - 3

ER -